SCM
VRTX icon

Shelton Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Shelton Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16.2M Sell
36,379
-862
-2% -$402K 0.36% 66
2025
Q4 		$16.9M Buy
37,241
+562
+2% +$242K 0.33% 74
2025
Q3 		$14.4M Sell
36,679
-16,336
-31% -$6.83M 0.31% 79
2025
Q2 		$23.6M Sell
53,015
-336
-0.6% -$155K 0.54% 36
2025
Q1 		$25.9M Sell
53,351
-1,280
-2% -$596K 0.62% 33
2024
Q4 		$22M Buy
54,631
+647
+1% +$300K 0.55% 32
2024
Q3 		$25.1M Buy
53,984
+6,276
+13% +$3.01M 0.64% 26
2024
Q2 		$22.4M Buy
47,708
+230
+0.5% +$99.8K 0.61% 28
2024
Q1 		$19.8M Buy
47,478
+4,354
+10% +$1.84M 0.56% 35
2023
Q4 		$17.5M Buy
43,124
+12,821
+42% +$4.74M 0.56% 32
2023
Q3 		$10.5M Buy
30,303
+6,534
+27% +$2.29M 0.39% 53
2023
Q2 		$8.36M Buy
23,769
+907
+4% +$306K 0.3% 74
2023
Q1 		$7.2M Buy
22,862
+2,614
+13% +$784K 0.3% 89
2022
Q4 		$5.85M Sell
20,248
-4,854
-19% -$1.48M 0.61% 34
2022
Q3 		$7.27M Buy
25,102
+344
+1% +$99K 0.35% 78
2022
Q2 		$6.98M Hold
24,758
– – 0.31% 83
2022
Q1 		$6.46M Buy
24,758
+481
+2% +$114K 0.24% 93
2021
Q4 		$5.33M Buy
24,277
+477
+2% +$92.8K 0.19% 117
2021
Q3 		$4.32M Sell
23,800
-8,400
-26% -$1.64M 0.17% 140
2021
Q2 		$6.49M Hold
32,200
– – 0.25% 89
2021
Q1 		$6.92M Buy
32,200
+10,388
+48% +$2.28M 0.24% 94
2020
Q4 		$5.16M Hold
21,812
– – 0.23% 94
2020
Q3 		$5.93M Hold
21,812
– – 0.25% 84
2020
Q2 		$6.33M Buy
21,812
+234
+1% +$63.4K 0.35% 60
2020
Q1 		$5.13M Sell
21,578
-377
-2% -$86.5K 0.37% 54
2019
Q4 		$4.81M Sell
21,955
-731
-3% -$148K 0.27% 77
2019
Q3 		$3.84M Sell
22,686
-3,366
-13% -$595K 0.23% 89
2019
Q2 		$4.78M Buy
26,052
+21,601
+485% +$3.78M 0.28% 70
2019
Q1 		$24.2K Sell
4,451
-19,744
-82% -$3.65M 0.1% 209
2018
Q4 		$4.01M Hold
24,195
– – 0.27% 80
2018
Q3 		$4.66M Hold
24,195
– – 0.27% 84
2018
Q2 		$4.11M Sell
24,195
-1,000
-4% -$155K 0.26% 90
2018
Q1 		$4.11M Buy
25,195
+2,122
+9% +$347K 0.27% 85
2017
Q4 		$3.46M Hold
23,073
– – 0.22% 99
2017
Q3 		$3.51M Hold
23,073
– – 0.24% 97
2017
Q2 		$2.97M Buy
23,073
+5,111
+28% +$615K 0.21% 108
2017
Q1 		$1.96M Buy
17,962
+1,000
+6% +$88K 0.14% 137
2016
Q4 		$1.25M Hold
16,962
– – 0.1% 204
2016
Q3 		$1.48M Hold
16,962
– – 0.12% 157
2016
Q2 		$1.46M Sell
16,962
-962
-5% -$83.1K 0.13% 145
2016
Q1 		$1.43M Buy
17,924
+1,678
+10% +$152K 0.13% 151
2015
Q4 		$2.04M Buy
16,246
+701
+5% +$84.6K 0.2% 103
2015
Q3 		$1.62M Buy
15,545
+2,517
+19% +$323K 0.18% 119
2015
Q2 		$1.61M Sell
13,028
-897
-6% -$113K 0.17% 122
2015
Q1 		$1.64M Buy
13,925
+2,359
+20% +$283K 0.18% 118
2014
Q4 		$1.37M Buy
11,566
+1,994
+21% +$225K 0.16% 127
2014
Q3 		$1.07M Buy
9,572
+1,007
+12% +$95.9K 0.14% 137
2014
Q2 		$811K Buy
8,565
+1,725
+25% +$121K 0.11% 191
2014
Q1 		$484K Buy
6,840
+760
+13% +$60.2K 0.07% 337
2013
Q4 		$452K Sell
6,080
-22,141
-78% -$1.54M 0.07% 350
2013
Q3 		$2.14M Buy
28,221
+248
+0.9% +$19.7K 0.36% 65
2013
Q2 		$2.23M Buy
+27,973
New +$2.06M 0.41% 55

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Shelton Capital Management's VRTX Position: Q1 2026 in Review

Shelton Capital Management reduced its Vertex Pharmaceuticals (VRTX) stake by 2.3% in Q1 2026, selling an estimated $402K and leaving 36,379 shares worth $16.2M. The position accounts for 0.36% of the portfolio, ranked #66.

Shelton Capital Management first reported a position in VRTX in Q2 2013 and has held it in 52 quarters since. The position peaked at $25.9M in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Shelton Capital Management held 36,379 shares of Vertex Pharmaceuticals worth $16.2M as of Q1 2026.
  • Shelton Capital Management sold 862 Vertex Pharmaceuticals shares in Q1 2026, an estimated $402K.
  • Vertex Pharmaceuticals made up 0.36% of Shelton Capital Management's portfolio in Q1 2026, its #66 holding.
  • Shelton Capital Management first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Shelton Capital Management's Vertex Pharmaceuticals position peaked at $25.9M in Q1 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Shelton Capital Management's 13F filing for Q1 2026, filed 15 May 2026.